1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Genital Herpes - Pipeline Review, H1 2017

Genital Herpes - Pipeline Review, H1 2017

  • March 2017
  • -
  • Global Markets Direct
  • -
  • 102 pages

Genital Herpes - Pipeline Review, H1 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape.

Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications.

Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Genital Herpes - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Genital Herpes - Overview
Genital Herpes - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Genital Herpes - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Genital Herpes - Companies Involved in Therapeutics Development
Abivax SA
Admedus Ltd
AiCuris GmbH and Co KG
Biomere LLC
Foamix Pharmaceuticals Ltd
Genocea Biosciences Inc
GenVec Inc
Immune Design Corp
JN-International Medical Corp
N and N Pharmaceuticals Inc
NanoBio Corp
NanoViricides Inc
Profectus BioSciences Inc
Redbiotec AG
Sanofi Pasteur SA
Starpharma Holdings Ltd
Tomegavax Inc
Vaccibody AS
Vaxart Inc
Vical Inc
Genital Herpes - Drug Profiles
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
acyclovir - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
G-103 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GEN-003 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
genital herpes (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
genital herpes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
GV-2207 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
herpes simplex virus [type 1, 2] vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
herpes simplex virus 2 vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
HSV-529 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
NN-001 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
pritelivir - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Profavax HSV-1 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Profavax HSV-2 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecule for Genital Herpes - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Theravax HSV-1 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Theravax HSV-2 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
VCLHB-01 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
VCLHM-01 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
VTMX-004 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Genital Herpes - Dormant Projects
Genital Herpes - Discontinued Products
Genital Herpes - Product Development Milestones
Featured News and Press Releases
Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine
Jan 05, 2017: Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial
Dec 14, 2016: Genocea RandD Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs and Strategy
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016
Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data
Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial
Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits
Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months
Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016
Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing
Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging
Feb 03, 2016: Model helps decide drug dose for clinical testing
Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003
Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Genital Herpes, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Genital Herpes - Pipeline by Abivax SA, H1 2017
Genital Herpes - Pipeline by Admedus Ltd, H1 2017
Genital Herpes - Pipeline by AiCuris GmbH and Co KG, H1 2017
Genital Herpes - Pipeline by Biomere LLC, H1 2017
Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Genital Herpes - Pipeline by Genocea Biosciences Inc, H1 2017
Genital Herpes - Pipeline by GenVec Inc, H1 2017
Genital Herpes - Pipeline by Immune Design Corp, H1 2017
Genital Herpes - Pipeline by JN-International Medical Corp, H1 2017
Genital Herpes - Pipeline by N and N Pharmaceuticals Inc, H1 2017
Genital Herpes - Pipeline by NanoBio Corp, H1 2017
Genital Herpes - Pipeline by NanoViricides Inc, H1 2017
Genital Herpes - Pipeline by Profectus BioSciences Inc, H1 2017
Genital Herpes - Pipeline by Redbiotec AG, H1 2017
Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2017
Genital Herpes - Pipeline by Starpharma Holdings Ltd, H1 2017
Genital Herpes - Pipeline by Tomegavax Inc, H1 2017
Genital Herpes - Pipeline by Vaccibody AS, H1 2017
Genital Herpes - Pipeline by Vaxart Inc, H1 2017
Genital Herpes - Pipeline by Vical Inc, H1 2017
Genital Herpes - Dormant Projects, H1 2017
Genital Herpes - Dormant Projects, H1 2017 (Contd..1), H1 2017
Genital Herpes - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Genital Herpes, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Companies Mentioned
Abivax SA
Admedus Ltd
AiCuris GmbH and Co KG
Biomere LLC
Foamix Pharmaceuticals Ltd
Genocea Biosciences Inc
GenVec Inc
Immune Design Corp
JN-International Medical Corp
N and N Pharmaceuticals Inc
NanoBio Corp
NanoViricides Inc
Profectus BioSciences Inc
Redbiotec AG
Sanofi Pasteur SA
Starpharma Holdings Ltd
Tomegavax Inc
Vaccibody AS
Vaxart Inc
Vical Inc

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Toll Like Receptor 4 (hToll or CD284 or TLR4) - Pipeline Review, H2 2016’, provides in depth ...

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Pipeline ...

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

78 kda Glucose Regulated Protein (Endoplasmic Reticulum Lumenal Ca(2+) Binding Protein Grp78 or Heat Shock 70 kDa Protein 5 or Immunoglobulin Heavy Chain Binding Protein or HSPA5) - Pipeline Review, H2 ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.